Lazard Asset Management’s Integra LifeSciences IART Stock Holding History

Lazard Asset Management’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-534	Closed	-$18K	–	2325
2024 Q1	$18K	Buy	+534	New	+$21.4K	﹤0.01%	1849
2023 Q3	–	Sell	-1,092	Closed	-$44K	–	2369
2023 Q2	$44K	Hold	1,092	–	–	﹤0.01%	1873
2023 Q1	$62K	Buy	1,092 +277	+34%	+$15.6K	﹤0.01%	1727
2022 Q4	$45K	Hold	815	–	–	﹤0.01%	1872
2022 Q3	$34K	Hold	815	–	–	﹤0.01%	1946
2022 Q2	$44K	Hold	815	–	–	﹤0.01%	1871
2022 Q1	$52K	Hold	815	–	–	﹤0.01%	1722
2021 Q4	$54K	Sell	815 -16,797	-95%	-$1.14M	﹤0.01%	1703
2021 Q3	$1.21M	Buy	+17,612	New	+$1.24M	﹤0.01%	1035
2021 Q1	–	Sell	-1,157	Closed	-$75K	–	1924
2020 Q4	$75K	Hold	1,157	–	–	﹤0.01%	1262
2020 Q3	$54K	Buy	+1,157	New	+$55K	﹤0.01%	1169
2020 Q2	–	Sell	-1,091	Closed	-$48K	–	1690
2020 Q1	$48K	Buy	1,091 +751	+221%	+$39.4K	﹤0.01%	1186
2019 Q4	$19K	Buy	340 +122	+56%	+$7.26K	﹤0.01%	1244
2019 Q3	$13K	Buy	+218	New	+$13K	﹤0.01%	1228

Other funds holding IART

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Lazard Asset Management's IART Position: Q2 2024 in Review

Lazard Asset Management sold out of Integra LifeSciences (IART) in Q2 2024, closing a stake of 534 shares — an estimated $18K sold.

Lazard Asset Management first reported a position in IART in Q3 2019 and held it in 14 quarters. The position peaked at $1.21M in Q3 2021. 238 funds tracked by Wall St. Rank hold IART as of Q2 2024.

Lazard Asset Management reported no remaining Integra LifeSciences position as of Q2 2024 after selling out during the quarter.
Lazard Asset Management sold 534 Integra LifeSciences shares in Q2 2024, an estimated $18K.
Lazard Asset Management first reported a position in Integra LifeSciences in Q3 2019 and held it in 14 quarters.
Lazard Asset Management's Integra LifeSciences position peaked at $1.21M in Q3 2021.
238 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2024.

Based on Lazard Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.